The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
Official Title: A Phase 3b, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Participants With Generalized Myasthenia Gravis Switching From Intravenous Complement Component 5 Inhibitors to Subcutaneous Zilucoplan
Study ID: NCT05514873
Brief Summary: The purpose of the study is to evaluate the safety and tolerability of switching from intravenous (IV) complement component 5 (C5) inhibitors to subcutaneous (SC) Zilucoplan in study participants with generalized myasthenia gravis (gMG)
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Mg0017 50564, Scottsdale, Arizona, United States
Mg0017 50559, Los Angeles, California, United States
Mg0017 50593, Rancho Mirage, California, United States
Mg0017 50099, San Francisco, California, United States
Mg0017 50557, O'Fallon, Illinois, United States
Mg0017 50556, Chapel Hill, North Carolina, United States
Mg0017 50086, Charlotte, North Carolina, United States
Mg0017 50076, Columbus, Ohio, United States
Mg0017 50555, Austin, Texas, United States
Mg0017 50304, Dallas, Texas, United States
Mg0017 50111, Seattle, Washington, United States
Mg0017 50569, Greenfield, Wisconsin, United States
Name: UCB Cares
Affiliation: 001 844 599 2273
Role: STUDY_DIRECTOR